Vasculitic syndromes in hepatitis C virus: A review
Related Experiment Video
Updated: Mar 8, 2026
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Gaafar Ragab1, Mohamed A Hussein1
1Rheumatology and Clinical Immunology Unit, Department of Internal Medicine, Cairo University, Egypt.
Insights
Hepatitis C virus (HCV) associated vasculitis presents with diverse symptoms and is classified based on cryoglobulin presence. Direct antiviral agents offer a promising, safe treatment for cryoglobulinemic vasculitis.
Area of Science:
- Immunology
- Hepatology
- Clinical Medicine
Background:
- Hepatitis C virus (HCV) infection is linked to vasculitis, a significant extrahepatic manifestation.
- Vasculitis associated with HCV is categorized into cryoglobulinemic and non-cryoglobulinemic types, depending on the role of serum cryoglobulins.
- The link between HCV and cryoglobulinemia is a notable achievement in understanding immune responses.
Purpose of the Study:
- To review the clinical and pathological characteristics of HCV-associated vasculitis.
- To discuss the classification and management strategies for cryoglobulinemic vasculitis (CV).
- To highlight the efficacy of direct antiviral agents (DAAs) in managing CV.
Main Methods:
- Literature review of HCV-associated vasculitis, focusing on pathogenesis, epidemiology, clinical features, and pathology.
- Discussion of the validated 2014 classification criteria for CV.
- Analysis of management approaches based on disease severity and the impact of new therapeutic agents.
Main Results:
- HCV can infect lymphocytes, initiating immune responses that lead to vasculitis.
- Clinical manifestations are widespread, affecting multiple organ systems and increasing lymphoma risk.
- Direct antiviral agents demonstrate safety and effectiveness in treating CV.
Conclusions:
- HCV-associated vasculitis encompasses a broad spectrum of clinical presentations and pathologies.
- Effective management strategies are guided by disease severity, with DAAs offering a significant therapeutic advance.
- Prioritizing HCV eradication through mass campaigns is crucial for managing CV, particularly in regions with high HCV prevalence.
Abstract:
Vasculitis is a remarkable presentation of the extrahepatic manifestations of HCV. According to the presence or absence of cryoglobulins it is subdivided into two main types: cryoglobulinemic vasculitis and non cryoglobulinemic vasculitis based on the attribution of vasculitis to serum cryoglobulins as a pathogenic factor. The attribution of cryoglobulinemia to HCV represents a success story in the history of immunology, microbiology, and clinical medicine. HCV can bind to and invade lymphocytes, consequently triggering an immune response through different mechanisms. The epidemiology of the disease is well described and the clinical picture describes cutaneous, pulmonary, musculoskeletal, neurological, renal, endocrine, gastrointestinal, hepatic and cardiovascular manifestations. It may also be associated with sicca symptoms, an increased risk of lymphoma and serious catastrophic events. The pathology is well characterized. A classification criteria of the syndrome that was validated in 2014 is discussed. Management of CV is decided according to the presence and severity of its clinical presentation. It is divided into asymptomatic, mild, moderate, severe and life threatening disease. Recently introduced direct antiviral agents are proving safe and effective in the management of cryoglobulinemic vasculitis, and it is advocated that the two types of vasculitis be given prioritization in the Egyptian mass campaign to eradicate HCV.
Related Concept Videos
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:24Nephrotic Syndrome I : Introduction
01:23Rheumatic Heart Disease I: Introduction
01:14Myocarditis III: Medical Management
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...